CLL Monthly Minutes
A greater number of comorbidities alone may not be sufficient to predict patient survival; age and stage at diagnosis must be considered as well. Read More ›
The first phase 3 trial comparing these drugs shows that acalabrutinib has similar efficacy as ibrutinib with a lower risk of a worrisome side effect. Read More ›
Although the use of telemedicine has been increasing due to the COVID-19 pandemic, it has not completely replaced the need for in-person visits. Read More ›
A federal law protects consumers from receiving bills covering the balance of many out-of-network emergency medical services. Read More ›
Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study. Read More ›
The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered. Read More ›
Recent data suggest that patients with CLL who received treatment with a BTK inhibitor had a rate of developing a second cancer over twice as high as that expected in the general population. Read More ›
Targeted therapies continue to change the treatment landscape, improving outcomes beyond traditional chemoimmunotherapy. Read More ›
Although most employers are not passing costs to employees, the COVID-19 pandemic has raised uncertainty throughout the entire healthcare system. Read More ›
An analysis of 4 studies finds that acalabrutinib does not increase the risk of developing heart problems for patients with CLL. Read More ›